Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor

ACS Chemical Biology

Volumn 12, Issue 5, 2017, Pages 1183-1187

  Field, S Denise ^a   Arkin, Jacob ^a   Li, Jing ^a   Jones, Lyn H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MESSENGER RNA; PROTEIN KINASE TYK2; STAT PROTEIN; JAK2 PROTEIN, HUMAN; PF 956980; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; DELAYED HYPERSENSITIVITY; DOWN REGULATION; HUMAN; IMMUNOCOMPETENT CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; BINDING COMPETITION; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; IMMUNE SYSTEM; METABOLISM;

ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; CELLS, CULTURED; DOWN-REGULATION; HUMANS; IMMUNE SYSTEM; JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RNA, MESSENGER;

EID: 85019578794     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.7b00116     Document Type: Article

References (53)

1. Lai, A. C. and Crews, C. M. (2017) Induced protein degradation: an emerging drug discovery paradigm Nat. Rev. Drug Discovery 16, 101-114 10.1038/nrd.2016.211
2. Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., and Crews, C. M. (2011) Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins Nat. Chem. Biol. 7, 538-543 10.1038/nchembio.597
3. Tae, H. S., Sundberg, T. B., Neklesa, T. K., Noblin, D. J., Gustafson, J. L., Roth, A. G., Raina, K., and Crews, C. M. (2012) Identification of hydrophobic tags for the degradation of stabilized proteins ChemBioChem 13, 538-541 10.1002/cbic.201100793
4. Shi, Y., Long, M. J. C., Rosenberg, M. M., Li, S., Kobjack, A., Lessans, P., Coffey, R. T., and Hedstrom, L. (2016) Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome ACS Chem. Biol. 11, 3328-3337 10.1021/acschembio.6b00656
5. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 46, 3-26 10.1016/S0169-409X(00)00129-0
6. Lebraud, H., Wright, D. J., Johnson, C. N., and Heightman, T. D. (2016) Protein degradation by in-cell self-assembly of proteolysis targeting chimeras ACS Cent. Sci. 2, 927-934 10.1021/acscentsci.6b00280
7. Deshaies, R. J. (2015) Protein degradation: prime time for PROTACS Nat. Chem. Biol. 11, 634-635 10.1038/nchembio.1887
8. Toure, M. and Crews, C. M. (2016) Small-molecule PROTACS: new approaches to protein degradation Angew. Chem., Int. Ed. 55, 1966-1973 10.1002/anie.201507978
9. Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., and Crews, C. M. (2016) Modular PROTAC design for the degradation of oncogenic BCR-ABL Angew. Chem., Int. Ed. 55, 807-810 10.1002/anie.201507634
10. Polier, S., Samant, R. S., Clarke, P. A., Workman, P., Prodromou, C., and Pearl, L. H. (2013) ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system Nat. Chem. Biol. 9, 307-312 10.1038/nchembio.1212
11. Zhang, Y., Zhang, J., Liu, C., Du, S., Feng, L., Luan, X., Zhang, Y., Shi, Y., Wang, T., Wu, Y., Cheng, W., Meng, S., Li, M., and Liu, H. (2016) Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells Cancer Lett. 382, 176-185 10.1016/j.canlet.2016.08.026
12. Wu, H., Wang, W., Liu, F., Weisberg, E. L., Tian, B., Chen, Y., Li, B., Wang, A., Wang, B., Zhao, Z., McMillin, D. W., Hu, C., Li, H., Wang, J., Liang, Y., Buhrlage, S. J., Liang, J., Liu, J., Yang, G., Brown, J. R., Treon, S. P., Mitsiades, C. S., Griffin, J. D., Liu, Q., and Gray, N. S. (2014) Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma ACS Chem. Biol. 9 (5) 1086-1091 10.1021/cb4008524
13. Lobbestael, E., Civiero, L., De Wit, T., Taymans, J.-M., Greggio, E., and Baekelandt, V. (2016) Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation Sci. Rep. 6, 33897 10.1038/srep33897
14. Zhao, J., Molitor, T. P., Langston, J. W., and Nichols, R. J. (2015) LRRK2 dephosphorylation increases its ubiquitination Biochem. J. 469, 107-120 10.1042/BJ20141305
15. Fuji, R. N., Flagella, M., Baca, M., Baptista, M. A. S., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L., Jubb, A. M., Katavolos, P., Lee, D. W., Lewin-Koh, S.-C., Lin, T., Liu, X., Liu, S., Lyssikatos, J. P., O'Mahony, J., Reichelt, M., Roose-Girma, M., Sheng, Z., Sherer, T., Smith, A., Solon, M., Sweeney, Z. K., Tarrant, J., Urkowitz, A., Warming, S., Yaylaoglu, M., Zhang, S., Zhu, H., Estrada, A. A., and Watts, R. J. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung Sci. Transl. Med. 7, 273ra15 10.1126/scitranslmed.aaa3634
16. Skibinski, G., Nakamura, K., Cookson, M. R., and Finkbeiner, S. (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies J. Neurosci. 34, 418-433 10.1523/JNEUROSCI.2712-13.2014
17. Herzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T. J., Schmid, P., Danner, S., Schnell, C. R., Mueller, M., Kinzel, B., Grevot, A., Bolognani, F., Stirn, M., Kuhn, R. R., Kaupmann, K., van der Putten, P. H., Rovelli, G., and Shimshek, D. R. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice Hum. Mol. Genet. 20, 4209-4223 10.1093/hmg/ddr348
18. Beke, L., Kig, C., Linders, J. T. M., Boens, S., Boeckx, A., van Heerde, E., Parade, M., De Bondt, A., Van den Wyngaert, I., Bashir, T., Ogata, S., Meerpoel, L., Van Eynde, A., Johnson, C. N., Beullens, M., Brehmer, D., and Bollen, M. (2015) MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells Biosci. Rep. 35, e00267 10.1042/BSR20150194
19. Bryant, C., Scriven, K., and Massey, A. J. (2014) Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human leukemia and lymphoma cells Mol. Cancer 13, 147 10.1186/1476-4598-13-147
20. McNaughton, M., Pitman, M., Pitson, S. M., Pyne, N. J., and Pyne, S. (2016) Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells Oncotarget 7, 16663-16675 10.18632/oncotarget.7693
21. Chekler, E. L., Pellegrino, J. A., Lanz, T. A., Denny, R. A., Flick, A. C., Coe, J., Langille, J., Basak, A., Liu, S., Stock, I. A., Sahasrabudhe, P., Bonin, P. D., Lee, K., Pletcher, M. T., and Jones, L. H. (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities Chem. Biol. 22, 1588-1596 10.1016/j.chembiol.2015.10.013
22. Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R. B., and Marks, P. A. (2007) Histone deacetylase inhibitors selectively suppress expression of HDAC7 Mol. Cancer Ther. 6, 2525-2534 10.1158/1535-7163.MCT-07-0251
23. O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., and Laurence, A. (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention Annu. Rev. Med. 66, 311-328 10.1146/annurev-med-051113-024537
24. Yamaoka, K. (2016) Janus kinase inhibitors for rheumatoid arthritis Curr. Opin. Chem. Biol. 32, 29-33 10.1016/j.cbpa.2016.03.006
25. Xiong, H., Zhang, Z.-G., Tian, X.-Q., Sun, D.-F., Liang, Q.-C., Zhang, Y.-J., Lu, R., Chen, Y.-X., and Fang, J.-Y. (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells Neoplasia 10, 287-297 10.1593/neo.07971
26. Sinclair, A., Archibeque, I., Zhan, J., Liu, L., Emkey, R., Doherty, E., and Begley, C. G. (2011) Potency and selectivity assessment of small molecules against Janus kinase (JAK) 2: widely used AG490 inhibitor is neither potent nor selective for JAK2 Blood 118, 4780
27. Fiorucci, G., Percario, Z. A., Marcolin, C., Coccia, E. M., Affabris, E., and Romeo, G. (1995) Inhibition of protein phosphorylation modulates expression of the Jak family protein tyrosine kinases J. Virol. 69, 5833-5837
28. Changelian, P. S., Moshinsky, D., Kuhn, C. F., Flanagan, M. E., Munchhof, M. J., Harris, T. M., Whipple, D. A., Doty, J. L., Sun, J., Kent, C. R., Magnuson, K. S., Perregaux, D. G., Sawyer, P. S., and Kudlacz, E. M. (2008) The specificity of JAK3 kinase inhibitors Blood 111, 2155-2157 10.1182/blood-2007-09-115030
29. Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., and Lucet, I. S. (2009) Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 387, 219-232 10.1016/j.jmb.2009.01.041
30. Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., Hirsch, J. L., Kiefer, J. R., Leone, J. W., Fischer, H. D., Sommers, C. D., Huang, H. C., Jacobsen, E. J., Tenbrink, R. E., Tomasselli, A. G., and Benson, T. E. (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6 J. Mol. Biol. 400, 413-433 10.1016/j.jmb.2010.05.020
31. Steele, A. J., Prentice, A. G., Cwynarski, K., Hoffbrand, A. V., Hart, S. M., Lowdell, M. W., Samuel, E. R., and Wickremasinghe, R. G. (2010) The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment Blood 116, 4569-4577 10.1182/blood-2009-09-245811
32. Migita, K., Izumi, Y., Torigoshi, T., Satomura, K., Izumi, M., Nishino, Y., Jiuchi, Y., Nakamura, M., Kozuru, H., Nonaka, F., Eguchi, K., Kawakami, A., and Motokawa, S. (2013) Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds Clin. Exp. Immunol. 174, 356-363 10.1111/cei.12190
33. Dalmasso, A. P., Goldish, D., Benson, B. A., Tsai, A. K., Wasiluk, K. R., and Vercellotti, G. M. (2014) Interleukin-4 induces up-regulation of endothelial cell claudin-5 through activation of FoxO1: role in protection from complement-mediated injury J. Biol. Chem. 289, 838-847 10.1074/jbc.M113.455766
34. Leaker, B. Biomarker assay and methods for evaluating the effectiveness of protein tyrosine kinase inhibitors in the treatment of inflammatory lung disease. WO2016030697, 2016.
35. Yan, J., Li, B., Lin, B., Lee, P. T., Chung, T.-H., Tan, J., Bi, C., Lee, X. T., Selvarajan, V., Ng, S.-B., Yang, H., Yu, Q., and Chng, W.-J. (2016) EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma Blood 128, 948-958 10.1182/blood-2016-01-690701
36. Vento-Tormo, R., Company, C., Rodriguez-Ubreva, J., de la Rica, L., Urquiza, J. M., Javierre, B. M., Sabarinathan, R., Luque, A., Esteller, M., Aran, J. M., álvarez-Errico, D., and Ballestar, E. (2016) IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation Genome Biol. 17, 4 10.1186/s13059-015-0863-2
37. Johnson, S. E., Shah, N. P., Bajer, A. A., and LeBien, T. W. (2008) IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors J. Immunol. 180, 8109-8117 10.4049/jimmunol.180.12.8109
38. Telliez, J.-B., Dowty, M. E., Wang, L., Jussif, J., Lin, T., Moy, E., Balbo, P., Li, W., Zhao, Y., Crouse, K., Dickinson, C., Symanowicz, P., Hegen, M., Banker, M. E., Vincent, F., Unwalla, R., Liang, S., Gilbert, A. M., Brown, M. F., Hayward, M., Montgomery, J., Yang, X., Bauman, J., Trujillo, J. I., Casimiro-Garcia, A., Vajdos, F. F., Leung, L., Geoghegan, K. F., Quazi, A., Xuan, D., Jones, L. H., Hett, E., Wright, K., Clark, J. D., Thorarensen, A., and Li, L. (2016) Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition ACS Chem. Biol. 11, 3442-3451 10.1021/acschembio.6b00677
39. Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L. M., Shah, N. P., Treiber, D. K., and Knapp, S. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nat. Chem. Biol. 10, 305-312 10.1038/nchembio.1471
40. Upadhayaya, R. S., Kethiri, R. R., Vellanki, A., Lightfoot, J., Local, A., and Rice, W. G. (2016) Discovery of selective dual inhibitors of bromodomain protein BRD4 and JAK2 for treatment of hematologic malignancies Blood 128, 5212
41. Ember, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., and Schönbrunn, E. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 9, 1160-1171 10.1021/cb500072z
42. Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., Bradner, J. E., Taniere, P., O'Sullivan, B., Müller, S., Schwaller, J., Stankovic, T., and Knapp, S. (2013) PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains Cancer Res. 73, 3336-3346 10.1158/0008-5472.CAN-12-3292
43. Moodley, D., Yoshida, H., Mostafavi, S., Asinovski, N., Ortiz-Lopez, A., Symanowicz, P., Telliez, J.-B., Hegen, M., Clark, J. D., Mathis, D., and Benoist, C. (2016) Network pharmacology of JAK inhibitors Proc. Natl. Acad. Sci. U. S. A. 113, 9852-9857 10.1073/pnas.1610253113
44. Strober, W. (2015) Trypan blue exclusion test of cell viability Curr. Protoc. Immunol. 111, A3.B.1-3 10.1002/0471142735.ima03bs111
45. Shah, F., Louise-May, S., and Greene, N. (2014) Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG2 cell lines Bioorg. Med. Chem. Lett. 24, 2753-2757 10.1016/j.bmcl.2014.04.039
46. Smith, G. A., Uchida, K., Weiss, A., and Taunton, J. (2016) Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling Nat. Chem. Biol. 12, 373-379 10.1038/nchembio.2056
47. Keil, E., Finkenstädt, D., Wufka, C., Trilling, M., Liebfried, P., Strobl, B., Müller, M., and Pfeffer, K. (2014) Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation Blood 123, 520-529 10.1182/blood-2013-03-492157
48. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O., Leung, L., Weinstein, A., Marubayashi, S., Goel, A., Gönen, M., Estrov, Z., Ebert, B. L., Chiosis, G., Nimer, S. D., Bernstein, B. E., Verstovsek, S., and Levine, R. L. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy Nature 489, 155-159 10.1038/nature11303
49. Wang, Y., Fiskus, W., Chong, D. G., Buckley, K. M., Natarajan, K., Rao, R., Joshi, A., Balusu, R., Koul, S., Chen, J., Savoie, A., Ustun, C., Jillella, A. P., Atadja, P., Levine, R. L., and Bhalla, K. N. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells Blood 114, 5024-5033 10.1182/blood-2009-05-222133
50. Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K., Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K., Taldone, T., Bradner, J. E., Chiosis, G., and Levine, R. L. (2014) Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms Blood 123, 2075-2083 10.1182/blood-2014-01-547760
51. Saenz, D. T., Fiskus, W., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P., Shen, A., Mill, C. P., Sun, B., Qiu, P., Kadia, T. M., Pemmaraju, N., DiNardo, C., Kim, M.-S., Nowak, A. J., Coarfa, C., Crews, C. M., Verstovsek, S., and Bhalla, K. N. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia 2017, DOI: 10.1038/leu.2016.393.
52. Yu, L., Mohamed, A. J., Simonson, O. E., Vargas, L., Blomberg, K. E. M., Björkstrand, B., Arteaga, H. J., Nore, B. F., and Smith, C. I. E. (2008) Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB Blood 111, 4617-4626 10.1182/blood-2007-10-121137
53. Bunnage, M. E., Gilbert, A. M., Jones, L. H., and Hett, E. C. (2015) Know your target, know your molecules Nat. Chem. Biol. 11, 368-372 10.1038/nchembio.1813